Table 2.

Ongoing and currently recruiting phase III clinical trials involving CAR T-cell therapies for hematologic malignancies (22).

Intervention	Condition	Location	ClinicalTrials.gov Identifier
Anti-CD19 CAR T-cells with concurrent BTK inhibitor for BCL	BCL	Union Hospital, Wuhan, Hubei, China	NCT05020392
CAR-transduced autologous T cell intravenous infusion in subjects with R/R DLBCL with chemotherapy	R/R DLBCL	Multi-center study	NCT03391466
Anti-CD19 CAR T-cells with chemotherapy or blinatumomab in adults with B-ALL	B-ALL	Multi-center study	NCT04530565
BiRd regimen combined with BCMA CAR T-cell therapy in patients with MM	MM	The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China	NCT04287660
VRd regimen combined with autologous BCMA CAR T-cell therapy in patients with MM	MM	Multi-center study	NCT04923893
Autologous CAR T cell therapy targeting BCMA	MM	Multi-center study	NCT04181827
Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects with R/R Multiple Myeloma (RRMM)	MM	Siteman Cancer Center, Saint Louis, MO, USA Hackensack University Medical Center, NJ, USA Sarah Cannon Research Institute Center for Blood, TN, USA	NCT03651128
Intravenous autologous CD19 CAR T-Cells for R/R B-ALL	R/R B-ALL	UKM Medical Centre Bandar Tun Razak, Kuala Lumpur, Malaysia	NCT03937544
Tisagenlecleucel in adult patients with aggressive B-cell NHL	B-cell NHL	University of Chicago Medical Center, Hematology & Oncology, IL, USA Sarah Cannon, Research Institute, TN, USA	NCT03570892